Skip to main content
News Tag: news
Moving Research Forward through Legislative Advocacy
Read More
De-intensification and Intensification Treatments for High-Risk Prostate Cancer Patients Stratified by Genomic Risk (NRG-GU009, the “PREDICT-RT” Trial)
Read More
Phase 2 Double-Blinded Trial Combining Oligometastatic Radiotherapy with Androgen Deprivation Therapy (NRG-GU011)
Read More
NRG-CC005 “FORTE” Amendment #3 is Now Active
Read More
A Message from the Chairs of NRG Oncology’s Research Strategy Committee, 2021: The Year in Review
Read More
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer – Outcomes Presented Soon! (NRG-GY017)
Read More
NRG Oncology Trial Data Concludes Paclitaxel and Carboplatin Should be Considered the Standard of Care as First-line Treatment for Women with Uterine Carcinosarcoma
Read More
Barbara Good, PhD, to Retire from NRG Oncology and the NSABP Foundation
Read More
Bupropion Does Not Improve Sexual Desire for Female Cancer Survivors on NRG Oncology Clinical Study
Read More
Get to Know the Protocol Support Committee (PSC)
Read More